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Abstract
Background: Although common and often disabling in multiple sclerosis (MS), visual dysfunction is currently not
adequately accounted for in both clinical routine and MS trials. Sloan low contrast letter acuity (SLCLA) is a
standardised chart-based measure of visual function particular at low contrast and has been suggested as additional
visual component to the Multiple Sclerosis Functional Composite (MSFC). Here, we evaluate the relations between
SLCLA, retinal integrity, MSFC, and quality of life (QoL) in MS patients.
Methods: Cross-sectional analysis of retinal nerve fibre layer (RNFL) thickness, MSFC, SLCLA (2.5% and 1.25%
contrast levels), visual evoked potentials, and QoL (Short Form (SF) 36, National Eye Institute Visual Functioning
Questionnaire (NEIVFQ)) using baseline data of 92 MS patients from an ongoing prospective longitudinal trial.
Relations between RNFL thickness or P100 latency and SLCLA were analysed using generalised estimating
equations (GEE) accounting for intra-individual inter-eye dependencies and corrected for age, gender, and history of
optic neuritis. Pearson’s correlations were used to assess relations between SLCLA, MSFC, and QoL.
Results: SLCLA reflected RNFL thickness (p = 0.021) and P100 latency (p = 0.004) and predicted vision-related QoL,
reflected by the NEIVFQ39 subscores “general vision” and “near activities” (p < 0.008 for both). SLCLA did not predict
general QoL reflected by SF36. Implementing SLCLA into MSFC, thus creating a four-dimensional MSFC4, captured
aspects of disability reflected by the NEIVFQ39 subscores “general vision” (r = 0.42, p < 0.0001) and “near activity”
(r = 0.3, p = 0.014) which were not captured by standard MSFC3.
Conclusions: SLCLA at 2.5% and 1.25% contrast levels correlates with retinal morphology and P100 latency and
predicts some aspects of vision-related QoL in MS. More importantly, using a prospective cross-sectional approach
we provide evidence that extending the MSFC by SLCLA as an additional visual component increases the performance
of MSFC to capture MS-related disability. Longitudinal data on the relation between SLCLA, MSFC, and QoL will be
available in the near future.
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composite, Quality of life, Retinal nerve fibre layer thickness
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Background
Afferent persistent visual dysfunction is frequent in multiple
sclerosis (MS) [1] and is either due to incomplete recovery
from optic neuritis (ON) or to rather diffuse damage of the
optic pathway that may occur independent of ON [2-4].
According to a German study in which MS patients rated
vision as the second most important physical function after
ambulation, integrity of vision is of particular importance
[5]. Likewise, several studies consistently showed that visual
impairment compromises health related quality of life
(QoL) [6,7]. Yet in clinical routine, the importance of visual
function is not adequately accounted for, for a number of
reasons: i) substantial vagueness exists concerning the mor-
phological substrate of the visual deficit in patients without
ON history; ii) bedside parameters for assessment of visual
functions focus on high contrast (HC) visual acuity (VA)
which is insensitive to change and to more diffuse and sub-
tle visual dysfunction [8]; iii) potentially more sensitive mea-
sures like low contrast (LC) VA are rarely used in clinical
routine; iv) patient-reported outcomes such as QoL that
might disclose the impact of visual deficits on daily life are
hardly addressed outside clinical trials; and v) most QoL
questionnaires do not adequately capture vision-related as-
pects. Consequently, there is a need for better evaluation of
more elaborate yet easy to perform measures of visual func-
tion and vision-related QoL assessment in MS patients.
The Sloan low contrast letter acuity (SLCLA) charts
comprise a set of letter charts based on the standardised
format of the HC VA charts used in the early treatment
of diabetic retinopathy study (ETDRS), but with different
levels of contrast between letters (ranging from black to
light grey) on white background (Figure 1). LCVA test-
ing using SLCLA charts has been validated in MS pa-
tients and has been shown to capture unique aspects of
neurologic dysfunction that were not captured by stand-
ard disability rating scales [9-11]. Moreover, SLCLA cor-
related with health-related QoL in MS patients [12].
Since its introduction in the late 1990s the Multiple
Sclerosis Functional Composite (MSFC) has been estab-
lished as major secondary outcome parameter for deter-
mination of disability in clinical MS trials [13]. Importantly,
the MSFC accounts for the variability in health-related
QoL measures not reflected by the expanded disability sta-
tus scale (EDSS) [14]. Given the major shortcoming of the
MSFC that it completely disregards vision as frequently im-
paired dimension in MS [8] considerations exist to comple-
ment the original MSFC with a fourth, visual component
[8,15]; and SLCLA testing is considered a promising
candidate [10,15]. However, formal prospective evaluation
whether addition of SLCLA performance improves MSFC
information overall has not yet been performed [15].
Using the baseline data set of an ongoing trial on the
course of visual system parameters in MS patients we
here evaluated the relation of SLCLA, morphological
and functional visual system parameters, QoL, and MSFC
in MS patients cross-sectionally. In particular we investi-
gated whether implementation of SLCLA testing improves
the performance of the MSFC.
Methods
Patients
We used the baseline data set of an ongoing, mono-
centric, longitudinal observational trial that evaluates
changes of visual system parameters in MS patients over
time (NCT01272596). Patients, aged 18 – 65 years, with
a first episode of demyelinating CNS disease suggestive
of MS (clinically isolated syndrome, CIS) and patients
with definite MS according to the revised panel criteria
[16] who had either relapsing remitting (RR) or second-
ary progressive (SP) disease course were eligible without
restrictions regarding disease modifying treatments. Main
exclusion criteria were MS relapses within the previous
a)
b)
Figure 1 Sloan low contrast letter acuity charts. Depicted are Sloan
low contrast letter acuity charts at 100% (a) and 2.5% (b) contrast level.
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month, refractive errors > ± 8 dpt, and MS unrelated ret-
inal pathologies, e.g. glaucoma or diabetic retinopathy. Of
the 100 patients enrolled in the longitudinal trial, 92 pa-
tients were eligible for cross-sectional analysis. Eight pa-
tients had to be excluded because of exclusion criteria that
became evident after enrolment or during the study (glau-
coma, retinal ablation, severe myopia, unclear retinal
pathology). A detailed cohort overview is given in Table 1.
Ethical statement
The study was approved by the local ethics committee
and was conducted in accordance to the Declaration of
Helsinki in its currently applicable version and the applic-
able German laws. All participants gave informed written
consent.
Low contrast visual acuity
LCVA was tested using SLCLA charts at four different
contrast levels (100%, 10%, 2.5%, and 1.25%), meaning
that the 100% level represents VA at HC. The 10% level
was used for adaptation. SLCLA charts were standar-
dised according to the ETDRS VA charts with five letters
per line (Figure 1). Testing conditions were standardised
with respect to illumination of the examination room
(80-100 cd/m2), distance between patient and chart (2 m),
position of patients (sitting), correction of visus (best
available correction), and instructions given. The charts
were scored based on the number of letters identified cor-
rectly (letter score, maximum score 60) [9]. All SLCLA
tests were conducted binocularly (both eyes open) as this
approach integrates possibly relevant binocular summa-
tion/inhibition effects [17], hence providing a measure of
overall visual function closer to the “real life” situation
than monocular testing. SLCLA per contrast level is given
as number of letters identified correctly (max. 60).
Multiple sclerosis functional composite
The conventional MSFC battery (MSFC3), comprising
the 25 foot timed walk test (TWT), 9-hole peg test
(9HPT) and paced auditory serial addition test (PASAT)
was performed according to standardised procedures,
calculated according to the standard manual, and nor-
malised to this cohort [13]. A new “MSFC4” was created
which additionally included SLCLA testing at 2.5% or
1.25% contrast levels. The MSFC4 score was calculated
using SLCLA z-scores according to the formula (Z9HPT +
ZT25FW + ZPASAT + ZSloan)/4, as previously described [10].
Optical coherence tomography
Retinal nerve fibre layer (RNFL) thickness was determined
using spectral domain optical coherence tomography (SD-
OCT; Heidelberg Engineering, Germany; software version
5.1) according to previously reported scanning protocols
[2]. Briefly, RNFL thickness around the optic disc was ac-
quired using the 3.4 mm circle scan with the eye tracker
system activated, and the maximum number of averaging
frames in ART MEAN mode was tried to be achieved. All
scans were performed by trained operators and were
reviewed for scan quality according to the OSCAR IB con-
sensus criteria [18]. Only eyes that passed the quality re-
view were included in the analysis.
Visual evoked potentials
Standard checkerboard stimulation was used for gener-
ation of visual evoked potentials (VEP). The electrodes
were placed on Oz and Fz according to the “10-20 Inter-
national System”. The analysed period was 500 ms fol-
lowing each visual stimulus; the P100 latency (ms) was
recorded.
Quality of life questionnaires
For assessment of QoL both the validated German ver-
sions of the self-administered questionnaires Short Form
(SF) 36 and the National Eye Institute Visual Functioning
Questionnaire (NEIVFQ) were used. SF36 was analysed
according to normative data and scripts [19], providing the
aggregate summary measures physical component sum-
mary (PCS) and mental component summary (MCS). The
NEIVFQ, introduced in 1998 as a 51-item questionnaire,
consists of 12 individually rated subscales and an overall
composite (total) score [20]. Two additional versions com-
prising 39 and 25 items and a neuro-ophthalmic supple-
ment are now available which are increasingly used in
clinical MS research to address vision-related QoL aspects
Table 1 Cohort demographic and clinical data
Subjects n 92
Gender (n/%) Female 64/69.6
Age (years) Mean ± SD 41 ±11
Range 19-64
Disease duration (months) Mean ± SD 96 ±70
Range 2-295
Disease course (n/%) RRMS 65/70.7
CIS 21/22.8
SPMS 6/6.5
EDSS Median ± SD 2.0 ±1.4
Range 0-7.0
Eyes with ON history (n/%) No 122/66.3
Yes 62/33.7
RNFLT (μm) Mean ± SD 87.3 ±15.1
n = 184 eyes Range 40.6 – 122.5
P100 VEP latency (ms) Mean ± SD 115 ±16.7
n = 184 eyes Range 75 - 177
Abbreviations: EDSS expanded disability status scale, RNFLT retinal nerve fibre
layer thickness, SD standard deviation, VEP visual evoked potentials.
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[1,12,21,22]. Here, we used the 39 item version [23] as at
study initiation a validated German translation was avail-
able only for this version.
Statistical analysis
Statistical analysis was performed using SPSS 21 (IBM,
Somers, NY, USA). Distribution analysis of quantitative
measures was performed using skewness, kurtosis and
Kolmogorov-Smirnov tests. Pearson’s correlations were
used to assess relations between MSFC, SLCLA, and
QoL. Performance of MSFC4 was evaluated using partial
correlations controlling for MSFC3. Relations between
RNFL thickness or P100 latency and QoL were analysed
using generalised estimating equations (GEE), a statistical
model that accounts for intra-individual inter-eye depend-
encies. All GEE models were corrected for age, gender,
and ON history. Statistical significance was established at
p < 0.05. All analyses should be considered exploratory as
no previous sample size calculation or adjustment for
multiple testing was applied.
Results
92 patients were included in the cross-sectional analysis.
Basic demographic and clinical data are provided in
Table 1, a summary of VA at both HC and LC levels and
data on both general and vision-related QoL are given in
Table 2. While as expected, VA at 100% and 10% levels
showed strong ceiling effects, VA at 1.25% and particu-
larly at 2.5% levels showed a near-normal distribution
(Figure 2). Therefore, we focused on the 2.5% contrast
level and provided additional data derived from 1.25%
level where relevant.
Correlations of low contrast visual acuity with retinal
morphology and visual pathway function
To further characterise our cohort, RNFL thickness and
P100 latency were determined (Table 1). Given recent stud-
ies showing close relations between retinal morphology and
LCVA [24,25] we first investigated, whether SLCLA at the
2.5% level is predicted by RNFL thickness and, in a next
step, by P100 latency. Using GEE analyses, which account
for inter-eye relations in statistical models factoring ON
history, age, and gender we observed a significant correl-
ation between SLCLA at 2.5% and RNFL thickness (B =
4.562E-005; Standard Error (SE) = 1.983E-005; p = 0.021).
Similar data were observed at the 1.25% level (B = 6.598E-
005; SE = 2.468E-005; p = 0.008). Likewise, SLCLA at 2.5%
(B = -4.013E-005; SE = 1.508E-005; p = 0.008) and SLCLA
at 1.25% (B = -5.555E-005; SE = 1.920E-005; p = 0.004) were
inversely correlated with P100 latency.
Correlation of low contrast visual acuity with quality of life
We next investigated whether SLCLA reflects self-
administered QoL assessment in MS patients. In contrast
Table 2 Visual acuity at different contrasts and quality of life data
Mean Standard deviation Maximum Minimum
Visual acuity (letter score) Contrast levels
100% 58.5 3.0 60 42
10% 53.5 5.5 60 36
2.5% 41 7.5 55 23
1.25% 38 9.0 54 11
SF36
PCS 44.48 9.72 63.72 19.17
MCS 46.37 10.67 67.14 19.98
NEIVFQ
Total 88.08 8.02 99.44 58.11
General health 59.5 18.7 100 15
General vision 78.2 12.0 100 45
Eye pain 80.5 17.6 100 25
Near activity 87.3 12.6 100 41.7
Distance activity 91.4 9.4 115 62.5
Social functioning 96.2 7.3 100 66.7
Mental health 89.5 12.5 118.8 35
Role difficulties 78.5 17.9 100 31.3
Dependency 96.5 13.7 100 12.5
Driving 84.2 20.3 100 0
Color 98 7 100 75
Peripheral vision 88 15 100 50
Abbreviations: SF36 Short Form 36 quality of life questionnaire, NEIVFQ National Eye Institute Visual Function Questionnaire, PCS physical component score, MCS
mental component score.
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to previous reports [12], we did not observe a correlation
between SLCLA at 2.5% and 1.25% levels and both the
physical (PCS) and mental (MCS) component summary
scores of the SF36 (Table 3). Given that SF36 is not de-
signed to specifically capture vision-related QoL, we add-
itionally used the vision-specific NEIVFQ39 which revealed
a moderate correlation between SLCLA at the 2.5% (and
also 1.25%) level and the NEIVFQ39 subscores “general vi-
sion” and “near activities” (Table 3). SLCLA was not associ-
ated with the NEIVFQ39 total score, which also includes
subscores that seem rather irrelevant to MS patients like
ocular pain or peripheral vision. Importantly, neither the
total score nor any of the subscores was associated with VA
determined at the 100% contrast level (not shown).
Implementation of low contrast visual acuity into MSFC
A key question of our still ongoing longitudinal study is
whether the overall performance of MSFC would be im-
proved by implementation of LCVA. Here, in this cross-
sectional analysis of the baseline data of the longitudinal
trial we thus asked whether SLCLA at 2.5% level improves
the predictive value of MSFC with respect to QoL. There-
fore, we first assessed the correlation of standard MSFC3
with QoL as determined by SF36 (Table 3). We found that
the correlation of MSFC3 with the SF36 PCS (r = 0.324,
p = 0.004) was mainly driven by TWT, whereas no cor-
relation was observed between MSFC3 and the MCS.
When implementing SLCLA (2.5% and 1.25%) into a
four-dimensional MSFC4 we observed that MSFC3 and
MSFC4 performed similar well (for MSFC4: r = 0.328,
p = 0.003). This association was, however, completely
lost in partial correlation analyses controlling for MSFC3,
indicating that the correlation for MSFC4 and SLCLA can
be completely explained by disabilities captured already by
MSFC3.
Given the above described limitations of SF36 with re-
spect to visual aspects we then used the NEIVFQ39 as a
more vision-specific dependent variable. Both, MSFC3
and MSFC4 showed no correlation with total NEIVFQ39
scores but mild correlations with the subscores “near activ-
ities” and “role”. As these associations were mainly driven
by the 9-HPT component in MSFC3 and by SLCLA and/
or 9-HPT in MSFC4 (Table 3) we additionally performed
partial correlations for MSFC4 and NEIVFQ39, controlling
for MSFC3. Using this model revealed significant associa-
tions for the NEIVFQ39 subscores “general vision” (r =
0.42, p < 0.0001) and “near activities” (r = 0.3; p = 0.014).
Similar results were found at the 1.25% level (“general vi-
sion”: r = 0.41; p = 0.001; “near activities”: r = 0.27; p =
0.024), suggesting that MSFC4 captures some aspects of
vision-related QoL not covered by conventional MSFC3.
Discussion
Using the cross-sectional baseline data set of an ongoing
longitudinal trial on visual parameters in MS/CIS pa-
tients we here addressed the relations between SLCLA,
retinal integrity, VEP, health-related QoL, and disability.
Our main findings are i) SLCLA determined at 2.5%
contrast level is predicted by RNFL thickness and P100
latency; ii) QoL determined by SF36 PCS reflects pre-
dominantly ambulation and, to a lesser degree, upper ex-
tremity function but not visual function as assessed by
SLCLA; iii) in contrast, visual dysfunction in MS patients,
determined by SLCLA, is captured by the “general vision”
and “near activities” subscores of the NEIVFQ39; and iv)
a)
b)
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Figure 2 Distribution analysis of Sloan low contrast letter
acuity. Depicted is the distribution of letter scores derived from
Sloan low contrast letter acuity testing in the entire cohort at 2.5%
(a) and the 1.25% (b) contrast level.
Schinzel et al. BMC Neurology 2014, 14:31 Page 5 of 8
http://www.biomedcentral.com/1471-2377/14/31
implementation of SLCLA as additional component might
enhance the performance of the MSFC as it seems to cap-
ture visual dysfunction as QoL-relevant aspect of disability
not covered by the conventional MSFC.
In line with recent studies on retinal morphology in
relation to visual disability in MS [25,26] our data show-
ing a significant association between SLCLA and retinal
axonal integrity independent of a previous ON support
the hypothesis that SLCLA reflects diffuse neurodege-
nerative processes in the retina, which could either be
due to primary degeneration, secondary to subclinical
inflammation, or both. In addition to morphological as-
pects, SLCLA testing also seems to capture physiologic
function of the visual system as indicated by the signifi-
cant association with P100 latency. The ability of SLCLA
testing to capture visual deficits that have a major im-
pact on the QoL of MS patients but are not adequately
captured by standard visual assessments has been ad-
dressed in another study by the same group [12]. When
using the 25-item version of the NEIVFQ plus the 10-
Table 3 Pearson correlation analyses of quality of life, multiple sclerosis functional composite, and Sloan low contrast
letter acuity
TWT-z 9HPT-z PASAT-z MSFC3 SLCLA 2.5% z SLCLA 1.25% z MSFC4
(SLCLA 2.5%)
MSFC4
(SLCLA 1.25%)
SF36 PCS r 0.369 0.324 -0.004 0.324 0.197 0.177 0.328 0.329
p 0.001 0.004 0.97 0.004 0.078 0.114 0.003 0.003
MCS r 0.093 -0.015 -0.103 -0.013 -0.032 -0.016 -0.021 -0.016
p 0.415 0.893 0.361 0.913 0.775 0.887 0.855 0.891
NEIVFQ39 Total r 0.043 0.215 0.055 0.145 0.178 0.123 0.182 0.164
p 0.693 0.044 0.608 0.177 0.093 0.248 0.092 0.129
General health r 0.211 0.207 -0.007 0.197 0.082 0.072 0.191 0.194
p 0.05 0.053 0.95 0.065 0.441 0.5 0.076 0.072
General vision r 0.021 0.159 -0.081 0.049 0.279 0.274 0.149 0.149
p 0.85 0.139 0.45 0.647 0.008 0.009 0.168 0.168
Eye pain r -0.09 -0.047 0.107 0.001 0.042 0.019 0.02 0.014
p 0.409 0.661 0.315 0.992 0.698 0.859 0.851 0.899
Near activities r 0.177 0.259 0.046 0.213 0.348 0.317 0.302 0.295
p 0.101 0.015 0.664 0.046 0.001 0.002 0.004 0.006
Distant activities r -0.015 0.124 -0.13 -0.014 0.105 0.084 0.027 0.019
p 0.89 0.249 0.222 0.899 0.324 0.429 0.802 0.859
Social functioning r -0.021 0.116 -0.087 -0.002 0.122 0.092 0.042 0.031
p 0.846 0.28 0.413 0.988 0.252 0.387 0.696 0.774
Mental health r -0.031 0.158 -0.039 0.049 -0.082 -0.125 0.009 -0.007
p 0.779 0.143 0.713 0.653 0.443 0.242 0.931 0.946
Role difficulties r 0.091 0.239 0.199 0.264 0.032 -0.014 0.229 0.219
p 0.402 0.025 0.06 0.013 0.766 0.893 0.033 0.042
Dependen-cy r 0.043 0.129 -0.021 0.075 -0.048 -0.074 0.042 0.034
p 0.692 0.23 0.846 0.486 0.653 0.489 0.697 0.757
Driving r 0.289 0.175 0.078 0.128 0.229 0.2 0.185 0.169
p 0.015 0.144 0.513 0.289 0.053 0.092 0.125 0.163
Color r 0.019 0.066 0.006 0.048 0.062 0.022 0.065 0.05
p 0.865 0.55 0.957 0.665 0.569 0.842 0.557 0.654
Peripheral vision r 0.142 0.095 0.134 0.172 0.151 0.099 0.203 0.187
p 0.199 0.391 0.217 0.117 0.165 0.366 0.065 0.09
Abbreviations: SF36 Short Form 36 quality of life questionnaire, NEIVFQ National Eye Institute Visual Function Questionnaire, TWT timed walk test, 9-HPT 9-hole peg
test, PASAT paced auditory serial addition test (3 sec. version), SLCLA Sloan low contrast letter acuity, MSFC3 three-dimensional (conventional) multiple sclerosis
functional composite, MSFC4 four-dimensional multiple sclerosis functional composite including Sloan low contrast letter acuity, r Pearson correlation coefficient,
p P-value, PCS physical health composite score, MCS mental health composite score.
Data depicted in bold reflect statistically significant data (p < 0.05).
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item neuro-ophthalmic supplement in a cohort of 167 pa-
tients with RR or progressive MS, the authors observed
significant correlations between both HCVA and LCVA
with both total score and most of the subscores, with
“near activities” “role difficulties” and “driving” subscores
showing the strongest correlations. Notably, associations
between SLCLA and QoL were reported to remain signifi-
cant when controlling for HCVA. Interestingly, that study
also revealed significant correlations between SLCLA and
the PCS of SF36 in a sub-cohort of 115 patients. In con-
trast, in our cohort, LCVA was reflected only by the sub-
scores “general vision” and “near activities”, while HCVA
was not related to QoL. Moreover, in our study, SLCLA
did not predict QoL as determined by SF36, a difference
that cannot be explained by different sample sizes. Our
observation that only particular NEIVFQ subscores were
correlated with SLCLA raises the question which aspects
of visual demands in daily life are covered by the respect-
ive subscores. “General vision” can be considered a more
common aspect that is important in daily life. Thus, already
mild reduction of LCVA might easily interfere with the
“general vision” aspect. The item “near activities” reflects all
actions at near distance and is thus affected by tasks requir-
ing accurate execution or ability to distinguish small or pale
objects, e.g. reading, writing, or painting. Thus, correlation
of this aspect with impairment of LCVA seems to be likely.
In contrast, as ocular pain for example is not a typical fea-
ture in MS outside acute ON one would not expect inter-
ference with the “eye pain” subscore of the NEIVFQ. While
in the study by Mowry et al. [12] a different measure of
visual performance, a different version of NEIVFQ, and a
larger sample size was used, which impedes a direct com-
parison with our data and may account for some of the
observed discrepancies, the bottom line information of
both studies are that in MS reduction of SLCLA nega-
tively impacts QoL and that the NEIVFQ is a promising
tool to capture vision-related QoL. Our data strengthen
the roles of LCVA testing and NEIVFQ for evaluation of
visual disability and its impact on QoL in MS.
Against this background SLCLA testing is a promising
candidate to complement the current three-dimensional
MSFC3 by a fourth visual component in order to com-
pensate for its obvious limitation that it does not cover
visual dysfunction. Earlier retrospective studies already
suggested that such a four-dimensional MSFC4 would
indeed capture relevant visual aspects of disability not
covered by EDSS or standard MSFC [10]. A recent re-
view on disability outcome parameters in MS deemed
formal inclusion of SLCLA test in the MSFC appropriate,
but demanded prospective testing to confirm whether
such an extension improves MSFC performance overall
[15]. Here, we evaluated the inclusion of SLCLA in the
MSFC in a prospective approach. QoL was chosen as
dependent variable as this parameter is increasingly
considered important when evaluating disease progression
and treatment effects in MS. Despite the availability of
more MS-specific QoL tools we opted for the SF36 as this
tools has been used for the initial validation of the MSFC
and in numerous other trials [12,14]. In keeping with the
observation of Heesen at al. that in the self-concept of MS
patients ambulation has the highest significance [5] the
correlation between standard MSFC and the PCS of the
SF36 in our cohort was mainly driven by TWT. Although
vision was the second important function in the study by
Heesen [5], in our cohort this observation was not reflected
by SF36-determined QoL when SLCLA was included in a
model controlling for MSFC3. The most likely explanation
and the rationale for thereafter using the NEIVFQ is that
SF36 is too insensitive a measure with respect to vision.
Using NEIVFQ in the same model controlling for functions
captured by standard MSFC3 revealed that the inclusion of
SLCLA testing at the 2.5% (and 1.25%) level captured addi-
tional aspects of disability that affect at least some aspects
of vision-related QoL, reflected by the “general vision” and
“near activities” subscores. As a conclusion, these cross-
sectional findings may cautiously suggest implementation
of SLCLA testing in the MSFC as an option to increase the
ability of the MSFC to capture MS-relevant disability.
Several limitations of our study need to be addressed.
First, data are based on cross-sectional analyses of the
baseline data set of an ongoing clinical trial. Whether
MSFC4 is also superior to MSFC3 with respect to longitu-
dinal intra-individual changes of LCVA remains to be
evaluated; longitudinal data are underway. Second, the
majority of included patients had either CIS or RRMS with
a median EDSS of 2.0. Thus, our cohort represents rather
mildly disabled MS patients, and more severely disabled
patients or patients with progressive disease are certainly
under-represented. Third, we observed a few outliers with
rather unaffected SLCLA but low NEIVFQ39-scores. Ha-
ving a closer look at these particular patients, mainly the
NEIVFQ39 subscores “role”, “peripheral vision”, “mental
health”, “eye pain” and “dependency” were the worst rated.
Although these aspects are probably not closely related to
MS-specific aspects of visual disability we did not find any
other relevant ocular disease in these patients. Hence, we
refrained from excluding these patients from the analyses.
Conclusions
In accordance with previous data, SLCLA reflects both
retinal morphology and (patho)physiologic function of the
visual system and predicts vision-related QoL in MS as
determined by NEIVFQ39. More importantly, we here
showed in a prospective cross-sectional approach that
SLCLA is a promising tool for extending the MSFC by a
fourth visual component. Longitudinal data on the rela-
tion between SLCLA tests, MSFC and QoL will be avail-
able in 2014.
Schinzel et al. BMC Neurology 2014, 14:31 Page 7 of 8
http://www.biomedcentral.com/1471-2377/14/31
Competing interests
This work was supported by a limited research grant by Novartis Pharma to
JD. The author(s) declare that they have no further competing interests.
Authors’ contributions
JS evaluated the patients, analysed data and drafted the manuscript. HZ
evaluated the patients and made substantial contributions to analysis and
interpretation of data. FP made substantial contributions to conception and
design of the study and interpretation of data. KR and KH made substantial
contributions to acquisition and interpretation of data. AB supervised the
analysis and interpretation of data. JD was in charge of study conception
and design, supervised acquisition and interpretation of data and drafted the
manuscript. All authors critically revised the manuscript for important
intellectual content. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by German Research Foundation grant Exc. 257.
We thank our study nurse Katharina Stößlein for excellent assistance in
managing and organising this study.
Author details
1NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin,
Charitéplatz 1, 10117 Berlin, Germany. 2Clinical and Experimental Multiple
Sclerosis Research Center, Department of Neurology, Charité - Universitäts-
medizin Berlin, Berlin, Germany. 3Department of Neurology, Charité - Univer-
sitätsmedizin Berlin, Berlin, Germany.
Received: 27 September 2013 Accepted: 12 February 2014
Published: 20 February 2014
References
1. Jasse L, Vukusic S, Durand-Dubief F, Vartin C, Piras C, Bernard M, Pélisson D,
Confavreux C, Vighetto A, Tilikete C: Persistent visual impairment in mul-
tiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler
2013, 19:1618–1626.
2. Oberwahrenbrock T, Schippling S, Ringelstein M, Kaufhold F, Zimmermann H,
Keser N, Young KL, Harmel J, Hartung H-P, Martin R, Paul F, Aktas O, Brandt AU:
Retinal damage in multiple sclerosis disease subtypes measured by high-
resolution optical coherence tomography. Mult Scler Int 2012, 2012:530305.
3. Dörr J, Wernecke KD, Bock M, Gaede G, Wuerfel JT, Pfueller CF, Bellmann-Strobl J,
Freing A, Brandt AU, Friedemann P: Association of retinal and macular damage
with brain atrophy in multiple sclerosis. PLoS ONE 2011, 6:e18132.
4. Oberwahrenbrock T, Ringelstein M, Jentschke S, Deuschle K, Klumbies K,
Bellmann-Strobl J, Harmel J, Ruprecht K, Schippling S, Hartung H-P, Aktas O,
Brandt AU, Paul F: Retinal ganglion cell and inner plexiform layer thinning
in clinically isolated syndrome. Mult Scler 2013, 19:1887–1895.
5. Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM: Patient
perception of bodily functions in multiple sclerosis: gait and visual
function are the most valuable. Mult Scler 2008, 14:988–991.
6. Balcer LJ, Baier ML, Kunkle AM, Rudick RA, Weinstock-Guttman B, Simonian N,
Galetta SL, Cutter GR, Maguire MG: Self-reported visual dysfunction in
multiple sclerosis: results from the 25-Item National Eye Institute Visual
Function Questionnaire (VFQ-25). Mult Scler 2000, 6:382–385.
7. Cole SR, Beck RW, Moke PS, Gal RL, Long DT: The National Eye Institute
Visual Function Questionnaire: experience of the ONTT. Optic Neuritis
Treatment Trial. Invest Ophthalmol Vis Sci 2000, 41:1017–1021.
8. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A,
Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J,
Weinshenker B, Willoughby E: Recommendations from the National Multiple
Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol
1997, 42:379–382.
9. Balcer LJ, Baier ML, Pelak VS, Fox RJ, Shuwairi S, Galetta SL, Cutter GR, Maguire MG:
New low-contrast vision charts: reliability and test characteristics in patients
with multiple sclerosis. Mult Scler 2000, 6:163–171.
10. Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML,
Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE,
Stuart WH, Ying G-S, Galetta SL, Maguire MG, Cutter GR: Contrast letter acuity
as a visual component for the Multiple Sclerosis Functional Composite.
Neurology 2003, 61:1367–1373.
11. Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B,
Mass M, Balcer LJ: Low-contrast letter acuity testing captures visual
dysfunction in patients with multiple sclerosis. Neurology 2005,
64:992–995.
12. Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL,
Nano-Schiavi ML, Cutter GR, Maguire MG, Balcer LJ: Vision related quality
of life in multiple sclerosis: correlation with new measures of low and
high contrast letter acuity. J Neurol Neurosurg Psychiatry 2009, 80:767–772.
13. Fischer JS, Rudick RA, Cutter GR, Reingold SC: The Multiple Sclerosis
Functional Composite Measure (MSFC): an integrated approach to MS
clinical outcome assessment. National MS Society Clinical Outcomes
Assessment Task Force. Mult Scler 1999, 5:244–250.
14. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS: Clinical significance of
the multiple sclerosis functional composite: relationship to patient-
reported quality of life. Arch Neurol 2000, 57:1319–1324.
15. Cohen JA, Reingold SC, Polman CH, Wolinsky JS: Disability outcome
measures in multiple sclerosis clinical trials: current status and future
prospects. Lancet Neurol 2012, 11:467–476.
16. Polman CH, Reingold SC, Edan G, Filippi M, Hartung H-P, Kappos L, Lublin FD,
Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ,
Weinshenker BG, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2005
revisions to the “McDonald Criteria. Ann Neurol 2005, 58:840–846.
17. Pineles SL, Birch EE, Talman LS, Sackel DJ, Frohman EM, Calabresi PA,
Galetta SL, Maguire MG, Balcer LJ: One eye or two: a comparison of
binocular and monocular low-contrast acuity testing in multiple
sclerosis. Am J Ophthalmol 2011, 152:133–140.
18. Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, Petzold A:
The OSCAR-IB consensus criteria for retinal OCT quality assessment.
PLoS ONE 2012, 7:e34823.
19. Bullinger M, Kirchberger I: Fragebogen zum Gesundheitszustand (SF-36). KG:
Hogrefe-Verlag GmbH und Co; 1998.
20. Mangione CM, Berry S, Spritzer K, Janz NK, Klein R, Owsley C, Lee PP:
Identifying the content area for the 51-item National Eye Institute Visual
Function Questionnaire: results from focus groups with visually impaired
persons. Arch Ophthalmol 1998, 116:227–233.
21. Noble J, Forooghian F, Sproule M, Westall C, O’Connor P: Utility of the
National Eye Institute VFQ-25 questionnaire in a heterogeneous group
of multiple sclerosis patients. Am J Ophthalmol 2006, 142:464–468.
22. Ma S-L, Shea JA, Galetta SL, Jacobs DA, Markowitz CE, Maguire MG, Balcer LJ:
Self-reported visual dysfunction in multiple sclerosis: new data from the
VFQ-25 and development of an MS-specific vision questionnaire.
Am J Ophthalmol 2002, 133:686–692.
23. Franke G, Esser J, Voigtländer A, Mähner N: Der National Eye Institute –
Visual Function Questionnaire (NEIVFQ). Erste Ergebnisse zur
psychometrischen Überprüfung eines Verfahrens zur Erfassung der
Lebensqualität bei Sehbeeinträchtigten. Z Mol Psychol 1998, 7:178–184.
24. Bock M, Brandt AU, Kuchenbecker J, Dörr J, Pfueller CF, Weinges-Evers N,
Gaede G, Zimmermann H, Bellmann-Strobl J, Ohlraun S, Zipp F, Paul F:
Impairment of contrast visual acuity as a functional correlate of retinal
nerve fibre layer thinning and total macular volume reduction in
multiple sclerosis. Br J Ophthalmol 2012, 96:62–67.
25. Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson SB,
Wilson JA, Maguire MG, Galetta SL, Frohman E, Calabresi PA, Schuman JS,
Balcer LJ: Ganglion cell loss in relation to visual disability in multiple
sclerosis. Ophthalmology 2012, 119:1250–1257.
26. Saidha S, Syc SB, Durbin MK, Eckstein C, Oakley JD, Meyer SA, Conger A,
Frohman TC, Newsome S, Ratchford JN, Frohman EM, Calabresi PA: Visual
dysfunction in multiple sclerosis correlates better with optical coherence
tomography derived estimates of macular ganglion cell layer thickness
than peripapillary retinal nerve fiber layer thickness. Mult Scler 2011,
17:1449–1463.
doi:10.1186/1471-2377-14-31
Cite this article as: Schinzel et al.: Relations of low contrast visual acuity,
quality of life and multiple sclerosis functional composite: a cross-sectional
analysis. BMC Neurology 2014 14:31.
Schinzel et al. BMC Neurology 2014, 14:31 Page 8 of 8
http://www.biomedcentral.com/1471-2377/14/31
